MedTrace Logo

Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib

NCT00461929 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2009-02-13

No results posted yet for this study

Summary

In order to distinguish between clonal instability driven by imatinib in CML and actual changes with secondary clones induced by imatinib we would like to investigate the karyotype of non-CML patients treated with imatinib such as GIST patients.

Conditions

  • Chronic Myeloid Leukemia
  • Gastrointestinal Stromal Cell Tumors
  • Chromosome Abnormality

Interventions

PROCEDURE

bone marrow aspiration

Sponsors & Collaborators

  • Princess Margaret Hospital, Canada

    collaborator OTHER

  • Mount Sinai Hospital, Canada

    collaborator OTHER

  • Novartis

    collaborator INDUSTRY

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Jeff Lipton, MD · University Health Network, DMOH

  • Martin Blackstein, MD · MOUNT SINAI HOSPITAL

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00461929 on ClinicalTrials.gov